| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/12/2009 | EP2086979A2 Imidazoý1,2-b¨pyridazine and pyrazoloý1,5-a¨pyrimidine derivatives and their use as protein kinase inhibitors |
| 08/12/2009 | EP2086971A1 Crystalline forms of thiazolidinedione derivative and its manufacturing method |
| 08/12/2009 | EP2086962A1 (r) -5-methyl-4, 5-dihydro- pyrazole-1, 5-dicarboxylic acid 1- [( 4 -chlorophenyl) amide 5-{ [2-fluoro-4- (2-oxo-2h-pyridin-1-yl) -phenyl]amide) as a factor xa inhibitor |
| 08/12/2009 | EP2086957A1 Sulphamate benzothiophene derivatives |
| 08/12/2009 | EP2086943A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 08/12/2009 | EP2086938A1 Organic compounds |
| 08/12/2009 | EP2086933A2 Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| 08/12/2009 | EP2086644A2 Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders |
| 08/12/2009 | EP2086589A2 Ultrasound microbubble mediated genes delivery system |
| 08/12/2009 | EP2086549A1 Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound |
| 08/12/2009 | EP2086525A1 Method of radio-sensitizing tumors using a radio-sensitizing agent |
| 08/12/2009 | EP2086521A2 Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs |
| 08/12/2009 | EP2086520A1 Imatinib compositions |
| 08/12/2009 | EP2086505A2 Injectable depot composition and its process of preparation |
| 08/12/2009 | EP1981886B1 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors |
| 08/12/2009 | EP1874748B1 2 -aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitor (iap) modulators |
| 08/12/2009 | EP1831209B1 Cdc25 phosphatase inhibitors |
| 08/12/2009 | EP1682107B1 Anti-tumour terpene compounds |
| 08/12/2009 | EP1567150B1 Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics |
| 08/12/2009 | EP1559432B1 Hm1.24-utilizing cancer vaccines |
| 08/12/2009 | EP1514116B1 Oxaliplatin anti-resistance method |
| 08/12/2009 | EP1509529B1 Esters in position 20 of camptothecins |
| 08/12/2009 | EP1503756B1 Epothilone derivative for the treatment of hepatoma and other cancer diseases |
| 08/12/2009 | EP1501774B1 Polyunsaturated linear aldehydes and their derivatives with anti-radical activity |
| 08/12/2009 | EP1465912B9 Chimeric tnf ligands |
| 08/12/2009 | EP1429771B1 Bicyclic compounds as inhibitors of chemokine binding to us28 |
| 08/12/2009 | EP1423105B9 Combinations of dmxaa and other anti-cancer agents |
| 08/12/2009 | EP1409645B1 Probiotic lactobacillus salivarius strains |
| 08/12/2009 | EP1401376A4 Colloidal metal compositions and methods |
| 08/12/2009 | EP1392328B1 Medicament for protection in radiotherapy |
| 08/12/2009 | EP1385882B9 Peptides and related molecules that bind to tall-1 |
| 08/12/2009 | EP1379257B1 Prodrugs of anticancer agents employing substituted aromatic acids |
| 08/12/2009 | EP1224170B1 6-position substituted indoline, production and use thereof as a medicament |
| 08/12/2009 | EP1198589B9 Tenascin-c nucleic acid ligands |
| 08/12/2009 | EP1149111B1 Method and composition for angiogenesis inhibition |
| 08/12/2009 | EP1030675B1 Treatment of hematologic disorders |
| 08/12/2009 | EP0898580B9 Methods and means for inhibition of cdk4 activity |
| 08/12/2009 | EP0788360B3 Boronic ester and acid compounds, synthesis and uses |
| 08/12/2009 | CN101506239A Antihuman alpha9 integrin antibody and use of the same |
| 08/12/2009 | CN101506221A Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors |
| 08/12/2009 | CN101506211A 激酶拮抗剂 Kinase antagonists |
| 08/12/2009 | CN101506210A 2-phenoxy pyrimidinone analogues |
| 08/12/2009 | CN101506206A Inhibitors of Akt activity |
| 08/12/2009 | CN101506204A Human protein tyrosine phosphatase inhibitors and methods of use |
| 08/12/2009 | CN101506198A Substituted bicyclic and tricyclic thrombin receptor antagonists |
| 08/12/2009 | CN101506196A Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses |
| 08/12/2009 | CN101506188A Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity |
| 08/12/2009 | CN101506183A Human protein tyrosine phosphatase inhibitors and methods of use |
| 08/12/2009 | CN101506177A 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as JAK kinases inhibitors |
| 08/12/2009 | CN101506154A Compounds for treating proliferative disorders |
| 08/12/2009 | CN101505791A Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
| 08/12/2009 | CN101505788A Prophylactic and/or therapeutic agents for peripheral neuropathy |
| 08/12/2009 | CN101505780A Treatment of development-related disorders |
| 08/12/2009 | CN101505777A Composition for preventing and/or treating tumor containing component originating in the bark of tree belonging to the genus acacia |
| 08/12/2009 | CN101505768A Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
| 08/12/2009 | CN101505760A Combinations comprising staurosprorines |
| 08/12/2009 | CN101505755A Agent for overcoming resistance to anti-cancer agent |
| 08/12/2009 | CN101505753A Compounds and compositions for treatment of cancer |
| 08/12/2009 | CN101505727A Pharmaceutical composition for oral administration |
| 08/12/2009 | CN101503685A Anticancer recombinant adenovirus with tumour cell miR-221/222 as drug target, construction method and use |
| 08/12/2009 | CN101503677A Recombinant adenovirus of Survivin promoter regulated human NIS gene, construction method and use |
| 08/12/2009 | CN101503474A Human vascular endothelial cell growth inhibition factor jogged polypeptide, preparation thereof and use in targeted antineoplastic activity |
| 08/12/2009 | CN101503473A Targeted polypeptide for diagnosing and treating lung cancer in vivo and in vitro and use thereof |
| 08/12/2009 | CN101503461A Polypeptide with liver cancer apoptosis reducing function |
| 08/12/2009 | CN101503459A Bloody noun antibacterial peptide temporin-Lb, genes thereof and use in pharmacy |
| 08/12/2009 | CN101503453A Nucleic acid molecule CRYL1SI3 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503452A Nucleic acid molecule CRYL1SI32 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503451A Nucleic acid molecule CXSI2 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503450A Nucleic acid molecule CXSI3 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503449A Nucleic acid molecule CXSI32 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503448A Nucleic acid molecule CXSI22 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503447A Nucleic acid molecule CXSI2 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503446A Nucleic acid molecule CXSI1 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503445A Nucleic acid molecule SI-CYPJ-32 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503444A Nucleic acid molecule SI-CYPJ-3 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503443A Nucleic acid molecule SI-CYPJ-22 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503442A Nucleic acid molecule SI-CYPJ-2 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503441A Nucleic acid molecule SI-CYPJ-1 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503440A Nucleic acid molecule SI-CYPJ-12 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503439A Nucleic acid molecule SI-CYPJ-52 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503438A Nucleic acid molecule SI-CYPJ-5 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503437A Nucleic acid molecule SI-CYPJ-4 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503436A Nucleic acid molecule SI-CYPJ-42 and use thereof in anti-cancer medicine preparation |
| 08/12/2009 | CN101503423A Parachlorobenzoyl hydrazone organotin complex, preparation and use |
| 08/12/2009 | CN101503410A Method for preparing high-purity podophyllotoxin from Chinese podophyllum root |
| 08/12/2009 | CN101503407A Imidazopyridine compound |
| 08/12/2009 | CN101503402A 2-aniline pyrimidine derivative, as well as preparation and uses thereof |
| 08/12/2009 | CN101503400A Method for preparing multiple catechin monomers by separation of tea polyphenol or catechin mixing system |
| 08/12/2009 | CN101503396A Semisynthesis of paclitaxel |
| 08/12/2009 | CN101503394A High piperazine acetydrazide derivatives, and preparation and use thereof |
| 08/12/2009 | CN101503369A Method for preparing vanillyl acidamide compounds by interfacial reaction |
| 08/12/2009 | CN101503356A Novel method for preparing high-purity chlorogenic acid |
| 08/12/2009 | CN101502660A Medicine-carrying polylactic acid microcapsular ultrasound contrast agent and preparation method thereof |
| 08/12/2009 | CN101502654A Preparation method of high-gloss high-stability Elsinochrome silicon oxide nano granule and application thereof in preparing intravenous injection agent |
| 08/12/2009 | CN101502645A Compound medicament for treating malignant pleuroperitoneal cavity dropsy and use thereof |
| 08/12/2009 | CN101502642A Use of hepatitis B virus x protein and encoding gene thereof in preparing medicament for treating cancer of liver |
| 08/12/2009 | CN101502636A Pure medicinal formulation for treating cancer and preparation method thereof |
| 08/12/2009 | CN101502613A Body-strengthening fatigue-resisting lipid-lowering oral liquid and capsule |
| 08/12/2009 | CN101502611A Medicament for treating cancer and preparation method thereof |
| 08/12/2009 | CN101502607A Cordyceps sinensis and mushroom composition, Cordyceps sinensis and mushroom polysaccharide oral liquid, and preparation method thereof |